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Abstract
In order to expand the repertoire of antifungal compounds a novel, high-throughput pheno-
typic drug screen targeting fungal phosphatidylserine (PS) synthase (Cho1p) was developed
based on antagonism of the toxin papuamide A (Pap-A). Pap-A is a cyclic depsipeptide that
binds to PS in the membrane of wild-typeCandida albicans, and permeabilizes its plasma
membrane, ultimately causing cell death. Organisms with a homozygous deletion of the
CHO1 gene (cho1ΔΔ) do not produce PS and are able to survive in the presence of Pap-A.
Using this phenotype (i.e. resistance to Pap-A) as an indicator of Cho1p inhibition, we
screened over 5,600 small molecules for Pap-A resistance and identified SB-224289 as a
positive hit. SB-224289, previously reported as a selective human 5-HT1B receptor antago-
nist, also confers resistance to the similar toxin theopapuamide (TPap-A), but not to other
cytotoxic depsipeptides tested. Structurally similar molecules and truncated variants of SB-
224289 do not confer resistance to Pap-A, suggesting that the toxin-blocking ability of SB-
224289 is very specific. Further biochemical characterization revealed that SB-224289 does
not inhibit Cho1p, indicating that Pap-A resistance is conferred by another undetermined
mechanism. Although the mode of resistance is unclear, interaction between SB-224289 and
Pap-A or TPap-A suggests this screening assay could be adapted for discovering other com-
pounds which could antagonize the effects of other environmentally- or medically-relevant
depsipeptide toxins.
Introduction
Patients with a compromised immune system are prone to develop nosocomial infections
which can be fungal, bacterial, parasitic, or viral in nature. Candida spp. are pathogenic fungi
responsible for the majority of fungal infections arising within hospitals [1, 2]. Of these, the
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species found most often is Candida albicans [3]. This fungus most commonly causes mucosal
infections including vaginal infections and oral thrush, but it can also cause life-threatening
infections. The most serious of these include fungal endocarditis and systemic bloodstream
infections which have mortality rates around or greater than 30% [4, 5].
There are currently three primary classes of antifungals used to treat invasive Candida infec-
tions. The first line defense includes azoles (e.g. fluconazole) and echinocandins (e.g. caspofun-
gin). However, resistance and tolerance to these drugs can lead to treatment failures [6–9]. The
mainstay of second line defense is the polyene amphotericin B, a drug that must be carefully
administered due to its nephrotoxic potential [10, 11]. As a result of drug resistance, poor oral
availability, and toxic side effects including drug-drug interactions [12], there is a clear need
for new antifungal drugs to treat Candida infections.
Previously, the fungal phosphatidylserine (PS) synthase (Cho1p) was identified as a promis-
ing antifungal drug target for several reasons. First, Cho1p has been demonstrated to be
required for Candida albicans virulence in a mouse model of systemic infection [13]. Mice
infected with a strain of C. albicans where both alleles of the CHO1 gene are deleted (cho1ΔΔ)
were able to survive indefinitely, whereas mice infected with the wild-type strain succumbed to
infection within two weeks [13]. Second, the Cho1p enzyme is conserved among many patho-
genic fungi [13, 14]. Last, Cho1p is absent within mammals [13–16]. Based on these observa-
tions, we hypothesized that high affinity inhibitors of Cho1p should render the organism
unable to cause infection within a host, be active against a broad range of fungal pathogens,
and be highly selective with minimal side effects in mammals.
Based on this hypothesis, we set out to identify inhibitors of this pathway using a cell based
high-throughput screening approach. The assay is based on the action of a PS-dependent
toxin, papuamide A (Pap-A), which is a cyclic depsipeptide isolated from marine sponges of
the genus Theonella. Pap-A kills C. albicans and other yeasts by binding to PS in the membrane
and forming pores that disrupt the integrity of the membrane [17, 18]. We wished to exploit
the PS-specific nature of Pap-A toxicity and identify compounds that block PS synthesis or
alternatively interfere with PS metabolism, by selecting those small molecules that allow C.
albicans survival in the presence of Pap-A. Thus, the Pap-A killing assay was adapted into a
robust 384-well plate screening assay and tested against a reference set of bioactive compounds
including many known drugs.
This screen showed a good statistical window and yielded a promising hit. However, we
found that Pap-A resistance is not specific enough to conclude that a compound targets
Cho1p, as other mechanisms can be responsible for this protection phenotype. In this study we
describe the characterization of a positive hit, SB-224289, which in turn showed an interesting
and highly specific behavior that blocks Pap-A mediated cellular poisoning.
Materials and Methods
Strains used
The SC5314 (wild-type) strain of C. albicans and mutants used in this study have been previ-
ously described [13] and are as follows: cho1ΔΔ (YLC337), and cho1ΔΔ::CHO1 (YLC344). The
media used to culture strains was YPD (1% Bacto yeast extract, 2% Bacto peptone, and 2% dex-
trose (Thermo Fisher Scientific, San Jose, CA)) [19].
Compounds
The 5,760 bioactive compound library is a collated compound set of approved drugs (675 com-
pounds) and biologically active compounds that have been documented to interact with a
wide range of targets (approximately 5,095 compounds) including Sigma Aldrich’s Library of
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Pharmacologically Active Compounds (LOPAC), Prestwick, and Microsource compound
libraries. The library compounds were all independently verified for purity and identity by
UPLC-MS analysis. Papuamide A was obtained from Flintbox (David Williams and Raymond
Andersen, University of British Colombia, Canada). SB-224289 (Cat. # 1221), MG-624 (Cat.
# 1356), and valinomycin (VA; Cat. # 3373) were ordered from Tocris Bioscience. GMC 2–29
(Cat. # 1080) and SB-216641 (Cat. # 1085) were ordered from Axon MedChem. Staurosporine
(CGP 41251) was ordered from Selleckchem. Kahalalide F (KF) was a kind gift from Dr. Fer-
nando Albericio and Gerardo Acosta at the Institute for Research in Biomedicine, Barcelona,
Spain. Theopapuamide (TPap-A) was provided by Dr. Mark Hamann at University of Missis-
sippi, University, Mississippi, USA. Compounds 2945, 2946, 3047, and 3048 were synthesized
as described previously [20], and details of the synthesis and compound characterization are
provided in the Supporting Information (S1 File).
Papuamide A resistance assay
Strains were grown overnight in liquid YPD shaking at 30°C to saturation, and cultures were
diluted to 2 x 104 cells/ml in YPD. Compounds of interest were diluted to twice the working
concentration by serial dilution in a 96 well plate or by preparing separately and adding to the
wells directly, in a volume of 37.5 μl of YPD. Then 37.5 μl of cells at 2 x 104 cells/ml in YPD
were added. Plates were incubated at 37°C for 6 hours or 3 hours depending on the experiment,
and then 75 μl of YPD containing depsipeptide (Pap-A at 8 μg/ml, VA at 6 μg/ml, KF at 30 μg/
ml, or TPap-A at 12 μg/ml) were added to each well, diluting those concentrations by half. This
addition was followed by a 37°C overnight incubation.
Cell survival was measured the next day by fluorescence intensity or optical density. For
fluorescence intensity, Alamar Blue (Invitrogen, Waltham, MA) was added to the wells at a
1:10 dilution. Plates were allowed to incubate again at 37°C for 30 minutes to 2 hours until
color change was apparent. Fluorescence was then read at excitation 550 nm and emission 590
nm. For optical density, plates were removed from overnight incubation and absorbance was
read in a plate reader at a wavelength of 600 nm. All measurements were performed on a Cyta-
tion3 BioTek plate reader using Gen 5 software.
High throughput screen for Pap-A resistance
The 5,760 compound library was screened in a total of eighteen 384 well plates (Nunc) at a final
concentration of 50–75 μM. Approximately 0.155 μl of compound dissolved in DMSO were
inoculated into 10 μl of YPD in each well from ~10 mM stock plates using a BioMek robot with
pin tools. Wild-type and cho1ΔΔ (positive control strain) were grown in liquid YPD in a 30°C
shaker overnight and cultures were diluted to 104 cells/ml in YPD.10 μl were added to each well
of the 384 well plate containing the test compounds using a Wellmate. Plates were incubated for
6 hours at 37°C, and then 10 μl of YPD containing 12 μg/ml Pap-A was added to give a final
concentration of 4 μg/ml in 30 μl of YPD. Plates were then incubated for another 16 hours at
37°C to allow selection for Pap-A resistance. The following day, cell survival was measured by
adding 30% Alamar Blue (Invitrogen, Waltham, MA) using a Wellmate. Plates were allowed to
incubate again at 37°C for 2–3 hours. Fluorescence was then read at excitation 550 nm and
emission 590 nm on an Envision plate reader (Perkin Elmer, Waltham, MA). In each plate,
three of the columns of wells were used as controls. One column contained no compounds and
no cells and served as background control. The positive control column contained cho1ΔΔ plus
Pap-A, as it showed resistance. An additional control was wild-type with no drugs and no Pap-
A for maximal wild-type growth. The averaged background readings from the wild-type cells
plus compounds in the presence of Pap-A served as the negative control in each plate.
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Phosphatidylserine synthase assay
This procedure was done as described in [21, 22] with minor alterations. Cultures were grown
overnight and then diluted to approximately 0.1 OD600/ml in 1 L YPD, and were shaken at
30°C for 6 to 10 hours. Cells were harvested by centrifugation at 6,000 x g for 20 minutes. Pel-
lets were then transferred to 50 ml conical tubes and washed with water and re-pelleted. Super-
natant was removed and the wet weight of the samples was taken. Cell pellets were stored
overnight at -80°C. The following day, a cold mixture of 0.1 M Tris-Cl pH 7.5, 5 mM β-mer-
captoethanol (BME), 10% glycerol, and protease inhibitors 1.7 μg/ml PMSF, 1 μg/ml leupeptin,
and 1 μg/ml pepstatin (RPI, Corp., Mount Prospect, IL, USA) was added to the frozen pellets
(1 ml/g [wet weight]) and allowed to thaw on ice. Cells were lysed using a French press (three
passes at approximately 13,000 lb/in2). The homogenate was centrifuged at 4°C for 5 minutes
at 3,000 rpm to clear unbroken cells and heavy material. Supernatant was then spun again at
27,000 x g for 10 minutes at 4°C. For some experiments, the resulting supernatant was then
spun at 100,000 x g to collect the lower density membranes. Pellets were resuspended in 500 μl
to 1 ml of 0.1 M Tris-Cl pH 7.5, 5 mM BME, 10% glycerol, and protease inhibitors. This mix-
ture was aliquoted into microcentrifuge tubes and homogenized to break apart clumps, keeping
on ice as much as possible. Total crude protein concentration was determined using a Bradford
Assay. The optimal assay mixture contained 50 mM Tris-HCl pH 7.5, 0.1% Triton X-100, 0.5
mMMnCl2, 0.1 mM CDP-DAG (Avanti Polar Lipids, Alabaster, AL) added as a suspension in
1% - 20% Triton X-100, and 0.4–0.5 mg protein in a total volume of 0.1 ml. SB-224289 and
MG-624 were added to the reaction mixture at varying concentrations to monitor their ability
to inhibit [3H]-PS production. The PS synthase assay was performed by monitoring the incor-
poration of 0.5 mM L-serine spiked with 5% [3H]-L-serine (or 0.02 μM) (Cat# ART 0246, ARC,
Inc., St. Louis, MO, USA) into the chloroform-soluble product at 37°C for a predetermined
amount of time. The reaction was terminated by the addition of 1 ml chloroform: methanol
(2:1). Following a low-speed spin, 800–1000 μl of the supernatant was removed to a fresh tube
and washed with 200 μl 0.9% NaCl. Following a second low-speed spin, 400–500 μl of the
organic phase was removed to a new tube and washed with 500 μl of chloroform: methanol:
0.9% NaCl (3:48:47). Following a third low-speed spin, 200–300 μl was transferred into scintil-
lation vials (Thermo Fisher Scientific, San Jose, CA). Tubes were dried under the chemical
hood and 2.5 ml Cytoscint-ES liquid scintillation cocktail (MP Bio, Santa Ana, CA, USA) was
added to each tube and counted in a Packard TriCarb 2900TR Liquid Scintillation Analyzer.
Statistical analysis
Graphs were made using GraphPad Prism version 6.04. Unpaired t-tests were used to deter-
mine significance between results. RISE (Robust Investigation of Screening Experiments) soft-
ware was used to analyze data from the high throughput screen and was used to calculate Z-
factors, identify 95th and 99th quantile data, and identify compounds that yielded hits of greater
than 90% of positive control (cho1ΔΔ).
Results
Screen for compounds that confer Pap-A resistance
A novel screen was developed with an original goal of identifying compounds that inhibit the
Cho1p PS synthase enzyme. This screen utilizes the unique activity of Pap-A, a toxin isolated
from Theonella spp. of sponges [23]. Pap-A has been shown to selectively compromise the
integrity of membranes containing PS [17, 18]. As a result, Pap-A is toxic to wild-type C. albi-
cans. However, the cho1ΔΔmutant, which lacks Cho1p, and thus has no PS in its membranes,
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is able to survive in the presence of Pap-A (Fig 1) [13]. A reintegrated strain, cho1ΔΔ::CHO1,
which has one allele of CHO1 and intermediate levels of PS [13], shows intermediate resistance
(Fig 1). This feature of Pap-A was employed as a selection tool in our screen to identify those
compounds that inhibit Cho1p. We hypothesized that some compounds that allow wild-type
growth in the presence of Pap-A would do so by decreasing levels of PS in membranes.
The screen was performed on approximately 5,600 diverse pharmacologically active com-
pounds as a representative set of chemical space. Each plate contained a column for each con-
trol: 1) cho1ΔΔ + Pap-A as a positive control 2) no cells/no Pap-A as a background control 3)
wild-type cells with no drugs or Pap-A for a wild-type growth control. The remainder of the
plate was reserved for compound testing by pin transfer, and served as a control for back-
ground of wild-type cells killed by Pap-A.
The majority of test wells (black open circles in Fig 2), which contained cells that were killed
by Pap-A, read near the no drug/no cell background control (red circles, Fig 2). Compounds
were tested at a final concentration of 50–75 μM for their ability to confer resistance to wild-
type C. albicans against a lethal dose of Pap-A (4 μg/ml). After incubation overnight, the viabil-
ity indicator Alamar Blue was added and fluorescence was measured at 590 nm as a proxy for
survival. Of the tested compounds, 21 (filled in blue circles) showed viability greater than or
equal to 90% of the cho1ΔΔ positive control (green circles) (Fig 2). These 21 compounds, were
considered first round positive hits and were selected and tested for reproducibility in provid-
ing Pap-A resistance. Of these 21 first round hits, two compounds reproducibly conferred Pap-
A resistance to the wild-type cells: SB-224289, a serotonin receptor antagonist [24], and MG-
624, a nicotinic acetylcholine receptor antagonist (Fig 3A).
Dose response curves were performed to determine the lowest concentrations of SB-224289
and MG-624 that could confer Pap-A resistance. Serial dilutions starting at 200 μM revealed
that SB-224289 could confer resistance down to 25 μM, while MG-624 was not consistently
effective at producing Pap-A resistance. We found that effects of SB-224289 at concentrations
above 400 μM could not be determined as this was greater than its solubility limit in the test
media. Efforts were focused on SB-224289, which showed consistent efficacy at a concentration
range from 100 μM to 25 μM (Fig 3B).
Identification of structural features that enable SB-224289 to confer Pap-
A resistance
In order to determine if Pap-A resistance is a property common to compounds with a similar
structure to SB-224289, we searched the other compounds screened in our library and found
one structural analog, GR-127935, which did not provide Pap-A resistance (Fig 4A). Two other
Fig 1. Resistance to Pap-A correlates with decreases in PS. The cho1ΔΔmutant is resistant to all
concentrations of papuamide A (Pap-A) indicating a total lack of PS. The cho1ΔΔ::CHO1 reintegrant strain is
more resistant to Pap-A than the wild-type (WT), but less resistant than the cho1ΔΔmutant.
doi:10.1371/journal.pone.0154932.g001
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structural analogs of SB-224289, GMC 2–29 and SB-216641, were tested to assess their ability
to confer Pap-A resistance to wild-type C. albicans (Fig 4A and 4C). We found that neither
analog rescued cells when compared with the SB-224289 control. This finding prompted us to
hypothesize that the areas of structural dissimilarity between SB-224289 and GR-127935,
Fig 2. Screen of FDA-approved bioactive compounds for those that confer Pap-A resistance. 5,760
compounds were screened for their effects on the growth of wild-typeC. albicans (open black circles) in the presence
of 4 μg/ml Pap-A. Cell growth was measured by transformation of the dye Alamar Blue over approximately 3 hours at
37°C. The cho1ΔΔ positive control cells growth in the presence of Pap-A with no compounds from the library are
represented by green circles. Compounds that allowed wild-type cells to display >90% (above the blue line) of the
growth of cho1ΔΔ control were designated with filled-in blue circles. Around 95% of the tested compounds showed
growth levels closer to the negative control, wells which contained no cells or drugs (open red circles). The horizontal
lines show the 99th quantile (purple) where 99% of the compounds exhibited growth and the 95th quantile (yellow)
95% of the compounds lie. The vertical lines divide the compounds by the 384-well plate in which they were screened
which correlate to plate numbers along the bottom. A full description of the screening method is found in Materials and
Methods.
doi:10.1371/journal.pone.0154932.g002
Fig 3. Compounds that conferred Pap-A resistance to C. albicanswild-type yeast. A) Structures of hits identified from
the screen. B) Comparison of the ability of the hits to confer Pap-A resistance to wild type C. albicans; SB-224289, MG-624,
and DMSO as a control.
doi:10.1371/journal.pone.0154932.g003
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Fig 4. The full structure of SB-224289 is required to provide Pap-A resistance. (A) and (B) show the structures of purchased or
synthesized analogs of SB-224289, respectively. In (C) and (D) 1x104 cells/ml were treated with a serial dilution of SB-224289, test
compounds or DMSO control, and then allowed to incubate for 6 hours at 37°C. Pap-A was added at either 4 μg/ml or 5 μg/ml after 6 hours
the plate was incubated at 37°C overnight. Alamar Blue was added and fluorescence signal measured at 590 nm indicating survival of cells.
doi:10.1371/journal.pone.0154932.g004
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GMC 2–29, and SB-216641—specifically the spirofuro-indole ring structure unique to SB-
224289—may be the key to conferring Pap-A resistance. We synthesized four SB-224289 ring
structure homologues, 2945, 2946, 3047, and 3048 (Fig 4B and S1 File), and tested their ability
to provide Pap-A resistance to wild-type C. albicans. Although we expected protection against
Pap-A at similar or even lower concentrations, none of the synthesized SB-224289 ring struc-
tures provided resistance to Pap-A (Fig 4B and 4D). These data indicate that the full molecular
structure of SB-224289 is required for producing Pap-A resistance to wild-type C. albicans.
Exploration of the Mechanism of Action of SB-224289
We hypothesized that SB-224289 inhibited the PS synthase enzyme, Cho1p, thus reducing lev-
els of PS and allowing wild-type cells to survive despite the activity of Pap-A. In order to test
this hypothesis, we performed a PS synthase assay to assess the activity of Cho1p with the addi-
tion of varying concentrations of SB-224289. Upon addition of SB-224289, no changes were
seen in the activity of the Cho1p enzyme as compared to the wild-type control. This indicated
that SB-224289 does not directly inhibit the PS synthase enzyme in this in vitro assay (Fig 5A).
Furthermore, a PS synthase assay was performed with MG-624 at varying concentrations.
Again, no PS synthase inhibition was observed in any concentration tested (Fig 5B).
To further investigate the mode of action of SB-224289, we assessed the compound’s ability
to inhibit PS synthesis in vivo. If the compound must be metabolized or modified internally in
order to inhibit Cho1p, we should see a decrease in PS levels only when treating live cells with
SB-224289. Previous studies showed that cho1ΔΔ, which has no PS, shows a distinct phenotype
of β (1–3)-glucan unmasking [25]. Based on this, we performed an assay to determine if treat-
ment with SB-224289 would cause the β (1–3)-glucan in the cell wall to become exposed. Cells
were treated with SB-224289 for 3 hours and then stained with β (1–3)-glucan antibody. How-
ever, epifluorescence microscopy showed no indication that β (1–3)-glucan was exposed in SB-
224289-treated cells. PS is also a precursor for the synthesis of phosphatidylethanolamine (PE),
in a pathway where PS is decarboxylated to form PE. As a result, the cho1ΔΔmutant, since it
lacks PS, requires ethanolamine in the medium so it can make PE from imported ethanolamine
via the Kennedy pathway. If SB-224289 is a PS synthase inhibitor, then it should have caused
ethanolamine auxotrophy in wild-type C. albicans, however, this was not the case.
Fig 5. SB-224289 and MG-624 Do Not Inhibit the Activity of Cho1p. PS synthase activity shown as counts
per minute per milligram of protein, quantifying 3H-L-serine incorporated into PS. Addition of varying
concentrations of SB-224289 (A) and MG-624 (B) did not have an inhibitory effect on PS production.
doi:10.1371/journal.pone.0154932.g005
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SB-224289 specifically blocks the activity of papuamides and not other
membrane disruptors
Naturally-produced depsipeptides share similar structures (Fig 6A) and can be medically rele-
vant like the antibiotic valinomycin (VA) produced from Streptomyces spp. [26, 27], the emetic
toxin cereulide produced by the foodborne pathogen Bacillus cereus [27–30], and anti-tumor
drug prospect kahalalide F (KF) found in sea slugs [31]. A previous study found that a seroto-
nin receptor antagonist, ondansetron hydrochloride, abolished the emetic effect of cereulide in
Asian house shrews [30]. Theopapuamide A (TPap-A) is a close structural relative of Pap-A
Fig 6. SB-224289 Protects Against Theopapuamide, but Not Other Depsipeptides. A. The structure of several depsipeptides are shown. For each of
these compounds, 1x104 cells/ml were treated with serially diluted concentrations of SB-224289 (SB) and were incubated for 3 hours at 37°C. Following
this incubation, B. 3 μg/ml valinomycin (VA), C. 15 μg/ml kahalalide F (KF), or D. 6 μg/ml theopapuamide (TA) was added and further allowed to incubate
overnight. Optical density (OD) was read at 600 nm the next day as a measure of cell survival.
doi:10.1371/journal.pone.0154932.g006
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and was previously shown to have potent antifungal activity [32, 33]. Based on these studies,
we were interested in determining if SB-224289 would block the activities of similar depsipep-
tide toxins.
First, we tested if SB-224289 could rescue cells from toxic levels of VA. We treated C. albi-
cans with serially diluted concentrations of SB-224289, followed by treatment with 3 μg/ml
of VA. We found that no concentration of SB-224289 was sufficient to provide protection to
cells (Fig 6B). We further measured the ability of SB-224289 to mitigate the toxicity of KF and
TPap-A (Fig 6C and 6D). SB-224289 was unable to protect wild-type cells against KF, but we
found that SB-224289 was able to provide protection against TPap-A.
Discussion
The screen described in this communication was originally intended to identify inhibitors of
the fungal PS synthase. However, the identified hit compound, SB-224289, does not inhibit PS
synthesis even though it interferes with the lethal effects of Pap-A on C. albicans cells that con-
tain PS. The evidence that SB-224289 does not block PS synthesis comes from several second-
ary screens based on the cho1ΔΔmutant’s characteristic phenotypes [13]. For example, the
cho1ΔΔmutant is an ethanolamine auxotroph because C. albicans uses PS as a precursor for
production of PE, a vital phospholipid, in one of its two PE synthesis pathways. Thus, ethanol-
amine must be supplemented in the medium so that the cho1ΔΔmutant can produce PE
through the alternative Kennedy Pathway. We saw no indication that treatment with SB-
224289 caused wild-type C. albicans to become an ethanolamine auxotroph, indicating that it
does not interfere with PS synthesis. A second useful phenotype is increased exposure of β (1–
3)-glucan in the cell wall upon loss of PS. The cause of this exposure in cho1ΔΔ is currently
unknown, but it is very specific to the loss of PS rather than PE [25]. As with the previous
assay, treatment with SB-224289 does not lead to exposure of β (1–3)-glucan, thus indicating
that it does not interfere with PS synthesis. Finally, SB-224289 did not interfere with PS synthe-
sis in an in vitro assay (Fig 5A).
The most interesting aspect of the blockade of the lethal effects of Pap-A on C. albicans by
SB-224289 is its specificity. Seven different analogs representing fragments of SB-224289 or the
entire molecule fail to rescue C. albicans from Pap-A-induced cytotoxicity. These results indi-
cate that the activity of SB-224289 is specific and relies on the entire structure of the molecule
(Fig 4), possibly, due to a specific three-dimensional conformation which could only be
adopted by the full SB-224289 molecule. In addition, SB-224289 could only inhibit the toxicity
of depsipeptides that were structurally highly similar. For example, we saw no indication that
SB-224289 provided protection to wild-type C. albicans treated with VA or KF (Fig 6). How-
ever, as expected, SB-224289 was able to abrogate the cytotoxicity of TPap-A, a close structural
relative of Pap-A (Fig 6) likely to bind PS as well. Altogether, these data suggest that there
might be a physical interaction between the two compounds that inhibits the toxic effects of
Pap-A. More specifically, structural differences in the tail regions of these related depsipeptides
may confer their selectivity. It is also possible that SB-224289 impacts cellular physiology in a
way that creates a protective response, but it is unclear what such a mechanism might entail.
Further studies are needed to understand the nature of the interaction between SB-224289
and Pap-A and the mechanism that leads to protection of C. albicans cells against Pap-A
toxicity. Although SB-224289 is clearly not acting by inhibiting Cho1p, the selective inactiva-
tion of the Pap-A toxin by SB-224289 indicates a path to the discovery of other compounds
that can inactivate similar membrane active toxins. In fact, the assay described herein could be
easily adapted from use with Pap-A to any number of membrane potent toxins to find antago-
nists. The compounds discovered by this approach would be useful for treatments against
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environmental toxins that occur during algal blooms that affect drinking water, food contami-
nation, etc. It could also be useful as a method for identifying potential drug interactions that
would counter-indicate compounds or combination therapies being considered as potential
anti-cancer or anti-microbial drugs.
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